PRSS3 and prostate carcinoma: Here, we show for the first time the potential of targeting mesotrypsin with a protein‐based inhibitor in vivo, whereas this potential has been investigated previously only in an in‐vivo prostate cancer model by genetically silencing mesotrypsin expression [9].